Skip to main content

Clinical Trials › NCT05123703

Active, Not RecruitingPhase 3

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

Sponsored by Hoffmann-La Roche

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
188
Target enrollment
11
U.S. states
May 2022
Start date
Sep 2029
Expected completion

Interventions / Treatments

OcrelizumabOcrelizumab PlaceboFingolimodFingolimod Placebo

Conditions studied

Relapsing-Remitting Multiple Sclerosis

Where this trial is running (13 sites)

California2 sites
La Jolla · San Francisco
Ohio2 sites
Cleveland · Columbus
Colorado1 site
Aurora
Washington D.C.
Maryland1 site
Baltimore
Boston
Missouri1 site
St Louis
New Brunswick
Philadelphia
Texas1 site
Houston
Virginia1 site
Charlottesville

MS centers in California

Compare treatment centers near a trial site by center type, providers and trials.

View California centers

More Phase 3 trials

Browse all Phase 3 MS trials
The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play